Mariańska B, Apel D, Seferyńska I, Maj S
Kliniki Hematologicznej Instytutu Hematologii i Transfuzjologii w Warszawie.
Wiad Lek. 1998;51(1-2):42-5.
36 patients with relapsed (29) or refractory (7) acute lymphoblastic or nonlymphoblastic leukaemia received regimens employing 1-3 courses of mitoxantrone (or idarubicin), intermediate doses of cytarabine and etoposide. Complete remission (CR) was achieved in 30% of patients (5/15 ALL, 6/21 AML, 5 cases of refractory and 6 of relapsed leukaemia). Duration of CR was 3-6+ months (3 patients are still alive). Toxicity of the treatment was acceptable, however 5 patients with severe granulocytopenia died from sepsis.
36例复发（29例）或难治性（7例）急性淋巴细胞白血病或非淋巴细胞白血病患者接受了包含1 - 3个疗程米托蒽醌（或伊达比星）、中等剂量阿糖胞苷和依托泊苷的治疗方案。30%的患者（15例急性淋巴细胞白血病患者中的5例、21例急性髓细胞白血病患者中的6例、5例难治性白血病患者和6例复发性白血病患者）实现了完全缓解（CR）。完全缓解持续时间为3 - 6 +个月（3例患者仍存活）。治疗毒性可接受，然而5例严重粒细胞减少的患者死于败血症。
